Wayne, Pa., April 22, 2026 (GLOBE NEWSWIRE) — Frontline Education, a leading provider of administration software purpose-built for K-12, today announced a series of advancements that accelerate its AI innovation across K-12—building momentum in how the company is applying AI to support school systems in the work ahead. 

Through the launch of its AI K-12 Advisory Council, a new partnership with AI for Education, and the continued expansion of AI-powered capabilities across its platform, Frontline is helping districts operate more efficiently, support their people, and prepare for a rapidly evolving future. 

“AI is quickly becoming foundational to how school systems operate and how educators are supported,” said Matt Strazza, Chief Executive Officer of Frontline Education. “Frontline is investing to lead in this space, ensuring our customers can adopt AI in ways that are intentional, trusted, and ultimately focused on improving outcomes for students.” 

Introducing the AI K-12 Advisory Council 

Frontline has launched its AI K-12 Advisory Council, bringing together a broad mix of district leaders from across the country spanning superintendents, HR, special education, IT, and operations.

These leaders are actively shaping how AI is introduced and applied within their districts, bringing forward both opportunity and challenge. 

The council’s mission is to: 

• Ground Frontline’s AI innovation in real district needs  

• Provide input into product development and high-impact use cases  

• Share insights on implementation and adoption  

• Help define responsible, effective AI use in K-12  

Early discussions reflect both urgency and optimism: 

“We’re preparing students for jobs that don’t even exist yet—and AI has to be part of how we think about that future,” shared one council member. 

“AI will become the way the work gets done,” added another. 

More information and member bios can be found here.  

Partnering with AI for Education 

Frontline also announced a partnership with AI for Education, a leading organization focused on helping educators apply AI in practical, responsible ways through evidence-based frameworks, training, and resources. 

Through this collaboration, Frontline will make practical GenAI literacy content from AI for Education, grounded in classroom experience and current research, available through its Professional Growth solutions, supporting learning that can be implemented, tracked, and embedded into everyday practice.   

Together, the organizations aim to ensure AI is not only innovative, but actionable—equipping districts with the tools and confidence to apply it effectively. 

Accelerating AI Across the Frontline Platform 

Frontline continues to expand AI-powered capabilities across its product suite to help districts move faster, reduce administrative effort, and improve the consistency and quality of critical decisions. Recent and upcoming innovations include: 

• IEP Goal Writer (Available Now): Helps special education teams create high-quality, standards-aligned draft goals more efficiently, reducing documentation time while supporting consistency and compliance. 

• R&H Resume Parser (Coming Soon): Helps hiring teams move from application review to candidate evaluation faster by turning unstructured resumes into organized, actionable candidate information. 

• School Health Management AI Capabilities (In Development): Helps school health teams quickly understand patterns and activity across the health office, improving visibility and enabling more informed follow-up. 

• Employee Evaluation Management (EEM) AI Advancements (In Development): Helps district leaders and school administrators drive more consistent, actionable evaluations with AI-supported insights. 

These capabilities are designed to fit into existing district workflows, helping customers realize value faster without introducing unnecessary complexity. As Frontline continues to expand AI across the platform, the focus remains the same: delivering practical innovation that helps school systems operate more effectively, support staff more consistently, and improve outcomes for students. 

#### 

About Frontline Education  

Frontline Education is a leading provider of school administration software, supporting more than 10,000 K-12 organizations nationwide. Our solutions span four key areas — Human Capital Management, Student Solutions, Business Operations, and Data & Analytics — helping school systems operate efficiently and deliver better outcomes for students and staff.  

A part of Roper Technologies (NASDAQ: ROP), Frontline combines long-term stability with a commitment to innovation in K-12 education. We’re proud to be recognized with a 2025 Glassdoor Best Places to Work award, reflecting our people-first culture and dedication to those who serve our schools. 

The post Frontline Education Accelerates AI Innovation Across K-12 with New Advisory Council and Strategic Partnership appeared first on Crypto Insider.

VICTORIA, Seychelles, April 22, 2026 (GLOBE NEWSWIRE) — BitMEX, one of the safest crypto exchanges, announced today the launch of its Trading Circuit Campaign, allowing traders to win their share of a weekly 100,000 USDT prize pool by completing a series of trading missions.

The campaign will run from 22 April 2026 at 12:00 PM (UTC) to 13 May 2026 at 11:59 PM (UTC). Users can participate at any time during the campaign period.

Rewards will be distributed across 3 categories:

• The Running Start: All traders can claim up to $300 in rewards by reaching trading volume targets.
• The Top Traders’ Edge: By placing in the top 20 for trading volume on selected contracts, participants can claim up to $200 in rewards.
• The Sprinters’ Bonus: All participants who achieve at least two tiers for all three weeks of the campaign’s duration can claim an annual TradingView Plus subscription.

To participate in the Trading Circuit Campaign, traders must be fully verified on BitMEX. Competition details and registration can be found here.

About BitMEX
BitMEX is the OG crypto derivatives exchange, providing professional crypto traders with a platform that caters to their needs through low latency, deep crypto native liquidity and unmatched reliability.

Since its founding, no cryptocurrency has been lost through intrusion or hacking, allowing BitMEX users to trade safely in the knowledge that their funds are secure. So too that they have access to the products and tools they require to be profitable.

BitMEX was also one of the first exchanges to publish their on-chain Proof of Reserves and Proof of Liabilities data. The exchange continues to publish this data twice a week – proving assurance that they safely store and segregate the funds they are entrusted with.

For more information on BitMEX, please visit the BitMEX Blog or www.bitmex.com, and follow Telegram, Twitter, Discord, and its online communities. For further inquiries, please contact press@bitmex.com.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/9c8c4f83-0753-4b7d-84c4-dc25a39cad2a

The post BitMEX Launches the Trading Circuit Campaign Featuring a 100,000 USDT Weekly Prize Pool appeared first on Crypto Insider.

MIAMI, April 21, 2026 (GLOBE NEWSWIRE) —  AMPLIFY is proud to announce its sponsorship of the inaugural Trucking Accident Strategy Academy (TASA), an advanced litigation education program founded by nationally recognized trial attorney Amanda Demanda and developed in collaboration with leading plaintiff trial lawyers.

Bridget Mercuri, Public Relations and Earned Media Director at AMPLIFY, will present a featured session titled “The Role of PR & Media in the Life Cycle of a Case.” The presentation will examine how strategic communications and earned media intersect with litigation strategy and how attorneys can responsibly integrate media considerations throughout the progression of a case.

The session will provide insight into how media narratives develop at each stage of litigation—from pre-suit investigation and filing through discovery, negotiation, and trial—and will address best practices for timing, messaging, and ethical engagement with reporters in high-profile or catastrophic injury matters.

“Media strategy has become an increasingly important component of modern litigation,” said Bridget Mercuri. “When used appropriately, earned media can help contextualize a case, inform the public, and support broader advocacy efforts while still respecting the legal process and client confidentiality.”

TASA brings together a faculty of leading trial lawyers and industry experts, including Felipe Blanco, Michael A. Haggard, and Stephen F. Cain, to deliver practical, trial-focused instruction in trucking accident litigation. The program is designed to strengthen attorneys’ understanding of crash investigation, regulatory frameworks governing the trucking industry, and courtroom strategy in complex commercial vehicle cases.

AMPLIFY’s sponsorship underscores its ongoing commitment to supporting plaintiff attorneys through strategic communications education and litigation-focused media advisory services.

The inaugural TASA session will be held on:

Date: April 28, 2026
Time: 9:00 AM – 3:00 PM
Location: 801 Brickell Ave, Suite 2100, Miami, FL 33131

About AMPLIFY

AMPLIFY is a revolutionary boutique legal marketing and PR agency with one mission: to help law firms scale through story. Based in Palm Beach, New York, Miami, NY/NJ, Scottsdale, Boston, Minneapolis, and Montreal, we craft world-class narratives that build credibility and demand attention. Our work spans PR, earned and social media, powerful websites, and industry-leading video — all AI-optimized with a deep focus on how your firm will be found. For more information, visit https://www.amplifylaw.ai/.

Media Contact:
Bridget Mercuri
Public Relations and Earned Media Director
AMPLIFY
Phone: (908)-612-3515
Email: bridget@amplifylaw.ai

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/3afab932-a8f6-44e9-bda8-b94430a1d3fd

The post AMPLIFY Sponsors Inaugural Trucking Accident Strategy Academy (TASA); Public Relations & Earned Media Director Bridget Mercuri to Present on Role of Media in Litigation Strategy appeared first on Crypto Insider.

LONDON, April 21, 2026 (GLOBE NEWSWIRE) — Spur Therapeutics today announced the presentation of new insights from its Phase 1/2 GALILEO-1 and GALILEO-2 trials of avigbagene parvec (FLT201), its investigational gene therapy for Gaucher disease type 1, during the International Working Group on Gaucher Disease (IWGGD) 2026 Symposium, May 3-6, 2026 in Trieste, Italy.

Presentation details:

Oral presentation:

Title: Two-year follow up of avigbagene parvec (FLT201) investigational AAV gene therapy in adults with Gaucher Disease type 1: Results from GALILEO-1 and GALILEO-2
Session 7: Therapies in Gaucher Disease (also available as a poster)
Date & Time: Wednesday May 6, 09:45 – 10:00
Presenter: Ida Schwartz, MD, PhD, Hospital de Clinicas de Porto Alegre, Brazil

Poster presentations:

Title: Trial in Progress: GALILEO-3, a Phase 3 Registrational Trial of avigbagene parvec (FLT201) Gene Therapy Candidate in Patients with Gaucher Disease type 1
Presenter: Reena Sharma, MD, Salford Royal Hospital, UK

Title: Impact of avigbagene parvec (FLT201) on markers of bone health in adults with Gaucher disease type 1
Presenter: Pilar Giraldo, MD, PhD, Hospital Universitario Quironsalud, Zaragoza, Spain

For more details on the symposium, please visit the IWGGD Symposium website.

About Spur Therapeutics 
Spur Therapeutics is a clinical-stage biotechnology company focused on developing life-changing gene therapies for debilitating chronic conditions. By optimizing every component of its product candidates, Spur aims to unlock the true potential of gene therapy to realize outsized clinical results. Spur is advancing a breakthrough gene therapy candidate for Gaucher disease and disease and a preclinical gene therapy candidate for Parkinson’s disease. Expanding our impact, and advancing the practice of genetic medicine. 

Toward life-changing therapies, and brighter futures. Toward More 

For more information, visit www.spurtherapeutics.com or connect with Spur on LinkedIn. 

Contact 
media@spurtherapeutics.com 

The post Spur Therapeutics To Present New Clinical Data on FLT201 for Gaucher Disease during the IWGGD 2026 Symposium appeared first on Crypto Insider.

Dublin, April 20, 2026 (GLOBE NEWSWIRE) — The “Biopharmaceutical Excipients Market (2nd Edition): Industry Trends and Global Forecasts: Distribution by Scale of Operation, Type of Modality, Type of Excipient, Chemical Components, Company Size, Source of Manufacturing, End User and Geographical Regions” report has been added to ResearchAndMarkets.com’s offering.

The global biopharmaceutical excipients market is estimated to grow from USD 3.6 billion in the current year to USD 6.3 billion by 2035, at a CAGR of 6.4% during the forecast period, till 2035

Over the years, the increasing popularity of biologics has resulted in a significant shift within the healthcare sector. In the past ten years, the annual rate of biopharmaceutical approvals (which includes monoclonal antibodies, recombinant proteins, vaccines, and gene therapies) by the USFDA has consistently risen, with biologics accounting for over 40% of all newly approved drugs.

As of October 2024, there are more than 12,700 biologic products undergoing clinical trials globally, emphasizing the level of innovation in this area. Considering their unique advantages over small molecules such as improved efficacy, precise targeting, and better safety profiles, biologics are projected to continue propelling advancements in treatments for cancer, autoimmune diseases, rare disorders, and genetic conditions. Nevertheless, biologics possess a complex structure and are naturally less stable than small molecules, making them susceptible to physical degradation (such as aggregation, precipitation, and denaturation) and chemical degradation (including oxidation, deamidation, and hydrolysis).

To overcome these challenges, various biopharmaceutical excipients, such as sugars (including sucrose and trehalose), amino acids (such as arginine), surfactants (for example, polysorbates), and polymeric agents (like PEGs), are employed to stabilize formulations, increase solubility, regulate pH and tonicity, and enhance overall bioavailability. In fact, more than 70% of marketed biologics depend on polysorbates as stabilizing agents, while bulking agents, antioxidants, and preservatives enhance their functional effectiveness.

Further, excipients have become essential for facilitating advanced drug product formats, including lyophilized vials, prefilled syringes, and ready-to-use liquid formulations. Ongoing innovations, especially in lipid-based excipients for mRNA vaccines and therapeutics, are expanding the landscape of excipients even further. Combined with the increasing tendency towards outsourcing and enhanced regulatory support for innovative excipients, the application of biopharmaceutical excipients is set for continued market growth throughout the forecast period.

BIOPHARMACEUTICAL EXCIPIENTS MARKET: KEY SEGMENTS

Commercial Scale of Operation Accounts for the Largest Share of Biopharmaceutical Excipients Market

In terms of scale of operation, the biopharmaceutical excipients market is segmented across preclinical / clinical and commercial scale. In the current year, the commercial scale segment occupies the higher biopharmaceutical excipients market share (close to 90%) and is likely to grow at a higher CAGR (6.8%) during the forecast period. This dominance is fueled by the increased demand for biologics, necessitating substantial amounts of excipients to maintain product stability, solubility, and efficacy during large-scale production. With an increasing number of biologic drugs moving into commercial manufacturing phases, the demand for excipients rises significantly, leading to a larger market share for commercial-scale operations.

Solid Tumors Segment to Hold the Highest Revenue in the Biopharmaceutical Excipient Market

In the current year, antibodies segment constitutes most of the biopharmaceutical excipient market size (around 50%) and is likely to grow at a higher CAGR (8.7%) during the forecast period. This results from the swift expansion and mass manufacturing of monoclonal antibodies and antibody-driven therapies, necessitating various excipients to maintain the stability, solubility, and safety of these intricate biologics.

Europe Accounts for the Largest Share of the Biopharmaceutical Excipients Market

In terms of geographical regions, Europe is likely to capture majority (35%) of the biopharmaceutical excipients market share in the current year, and this trend is unlikely to change in the future as well. This results from the significant presence of well-established biotech and pharmaceutical firms in the sector. The focus of major industry leaders drives substantial funding and speeds up the integration of AI technologies in pharmaceutical production. Further, this sector gains advantages from its developed pharmaceutical ecosystem, strong R&D capacities, and favorable regulatory framework, which enhances its leading position. Significantly, the Asia-Pacific market is expected to expand to the highest CAGR (7.7%) throughout the forecast period until 2035.

BIOPHARMACEUTICAL EXCIPIENTS MARKET: KEY INSIGHTS

• The current market landscape features the presence of close to 60 manufacturers that claim to offer services for biopharmaceutical excipients across the world; of these, majority (40%) are headquartered in Europe.
• Close to 50% of the companies manufacture polymer-based biopharmaceutical excipients; of these, majority (~65%) of the excipients are being used as stabilizers in drug formulations.
• Stakeholders are actively upgrading their existing capabilities in order to enhance their respective portfolios and gain a competitive edge over other players active in the biopharmaceutical excipients manufacturing domain.
• Majority of the deals inked in this domain were distribution agreements, indicating a strategic focus on expanding market reach and ensuring broad availability of specialized excipients across diverse geographic regions.
• Driven by the growing demand for biologics, CMOs have significantly expanded their existing capacities and capabilities; notably, majority of the expansion initiatives have been undertaken by players based in Europe.
• Our proprietary framework serves as a strategic tool for developers, enabling them to evaluate vendors based on their specific requirements for biopharmaceutical excipients manufacturing.
• Driven by the growing adoption of biologic therapies, innovations in multifunctional excipients, the biopharmaceutical excipients market is anticipated to witness robust growth in the coming years.
• Currently, majority of the market share is captured by antibodies subsegment owing to the widespread use of monoclonal antibodies, which play a vital role in targeted therapies for cancer, autoimmune, and infectious diseases.
• Carbohydrates sub-segment is estimated to capture most of the market share in the current year, due to the extensive use of starch, sucrose, and dextrose in drug formulations as stabilizers and bulking agents for biologics.

REASONS TO BUY THIS REPORT

• The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
• Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

COMPANIES FEATURED

• A&C Bio Buffer
• ABITEC
• Actylis
• Additive Manufacturing Customized Machines (AMCM)
• Aditya Chemicals
• ADM
• Advancion (formerly known as ANGUS Chemical)
• AmpTec
• Apothecon Pharmaceuticals
• Asahi Kasei
• Ashland
• Avanti Research
• Avantor
• Azelis
• Barentz
• BASF Pharma
• BENEO
• BIOGRUND
• BioNTech
• BioSpectra
• BOC Sciences
• Bonumose
• Brenntag
• Budenheim
• Cascade Chemistry (acquired by Actylis)
• CG Chemkalien
• c-LEcta
• Cole-Parmer
• Colorcon
• Corden Pharma
• CPI
• Crest Cellulose
• Croda
• DFE Pharma
• DKSH
• Dr. Paul Lohmann
• DuPont
• DURECT
• Enmex
• Erkang Pharmaceutical
• Evonik
• Finar
• Fuji Chemical
• Gangwal Healthcare
• Gattefosse
• Gelita
• Harro Hofliger
• Hawkins
• HOPAX
• Hosokawa Micron
• Ideal Cures
• IFF Pharma Solutions
• IMCD
• IMCoPharma
• Indchem International
• InnoCore Pharmaceuticals
• International Flavors & Fragrances
• InVitria
• Itacel
• JRS Pharma
• Kerry
• Kirsch Pharma
• KLK Kolb
• Kuraray
• Larodan
• Lazuline Biotech
• LBB Specialties
• Lipoid
• Lubrizol
• LyoHUB
• Maas Pharma Chemicals
• Meggle
• Merck KGaA
• Mitushi Biopharma
• Moderna
• Nagase Viita
• National Institute of Bioprocessing Research and Training (NIBRT)
• Nordic Bioproducts
• Nordmann
• PanReac AppliChem
• PCAS
• Pfanstiehl
• Pfizer
• Polykon Manufacturing
• Qualicaps
• ReForm Biologics
• Roquette
• Seppic
• Shanghai Huamao Pharmaceutical
• Shin-Etsu Chemical
• Sigachi
• Spectrum Chemical Manufacturing
• SPI Pharma
• Stanford University
• Sudeep Pharma
• TaBlitz
• Thermo Fisher Scientific
• Tomita
• TTY Biopharm
• Univar Solutions
• VAV Life Sciences
• Vikram Thermo
• Wilshire Technologies

MARKET SCOPE

Scale of Operation

• Preclinical / Clinical Scale
• Commercial Scale

Type of Modality

• Antibodies
• Vaccines
• Cell and Gene Therapies
• Proteins / Peptides
• Other Biologics

Type of Excipients

• Buffering Agents
• Lyoprotectant Agents
• Solubilizers and Surfactants
• Tonicity Agents
• pH Adjusting Agents
• Others

Chemical Components

• Carbohydrates
• Polymers
• Polyols
• Proteins / Amino Acids
• Others

Company Size

• Small Players
• Mid-sized Players
• Large and Very Large Players

Source of Manufacturing

• In-house
• Outsourcing

End User

• Contract Manufacturers
• Drug Developers
• Hybrid Players

Key Geographical Regions

• North America
• Europe
• Asia-Pacific
• Middle East and North Africa
• Latin America

ADDITIONAL BENEFITS

• Complimentary PPT Insights Packs
• Complimentary Excel Data Packs Covering All Analytical Modules
• Up to 15% Complimentary Content Customization
• In-Depth Report Walkthrough with the Research Team
• Complimentary Report Update if the Report is 6+ Months Old

For more information about this report visit https://www.researchandmarkets.com/r/qhe5xz

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

The post Biopharmaceutical Excipients Market Trends and Global Forecasts Report 2026-2035: Growing Adoption of Biologic Therapies and Innovations in Multifunctional Excipients to Bolster Growth appeared first on Crypto Insider.

London, UK, April 20, 2026 (GLOBE NEWSWIRE) — RedCloud Holdings plc (Nasdaq: RCT) (“RedCloud” or the “Company”), the company building intelligent infrastructure for global trade, today announced it is progressing the deployment of its RAID (Realtime AI for Distribution) engine in Turkey, moving from R&D into early-stage integration with one of the country’s leading distribution networks.

This development marks the next phase of RedCloud’s expansion in Turkey, transitioning from capability build to in-market execution. Following the establishment of its up to $50 million joint venture and the intended launch of its AI R&D hub at ITU Teknokent, RedCloud is now working alongside a leading national distributor to integrate RAID into active distribution environments in H1 FY’26.

This phase focuses on embedding RAID directly into the flow of trade, enabling more precise demand prediction, inventory positioning, and execution decisions across complex FMCG supply chains. It represents the first step toward enterprise deployment of RedCloud’s intelligence infrastructure within live market conditions.

With global supply chains facing renewed disruption, ongoing instability in the Middle East is constraining key trade routes, increasing volatility, and exposing structural weaknesses in how goods move globally. Critical corridors are under pressure, costs are shifting rapidly, and visibility across supply chains remains fragmented.

In this environment, the advantage shifts decisively to those who can act on data inside the flow of trade, not analyze it after the fact.

Mehmet Bostan, CEO and Co-Founder of RedCloud Türkiye, said, “Global supply chains are being reshaped in real time. What we are seeing in the Middle East is not a regional disruption, it is exposing how fragile and fragmented global trade infrastructure has become.”

“When critical routes are constrained and costs move this fast, the advantage shifts to those who can make decisions at speed, with precision, inside the flow of trade itself.”

Prof. Dr. Mustafa Ergen, Non-Executive Director of RedCloud said, “Turkey sits at the crossroads of Europe, Asia and the Middle East. As critical trade routes face unprecedented pressure, the ability to make intelligent decisions inside the flow of trade is no longer optional — it is existential. Embedding RAID into live distribution networks in Turkey will prove that this infrastructure works where it matters most.”

This progression will operationalize RedCloud’s joint venture model in Turkey combining local market infrastructure with the Company’s AI-driven intelligence layer. It also establishes a pathway for broader regional rollout as RAID moves toward full enterprise deployment.

The announcement follows RedCloud’s recently announced Saudi Arabia licensing agreement, reinforcing the Company’s strategy to scale globally through regional partnerships and embed intelligence directly into how trade operates across high-growth FMCG markets.

Together, the Turkey and Saudi agreements represent up to $80 million in contracted value, reflecting the early commercial scale of RedCloud’s intelligence infrastructure as it moves into advanced development and deployment across major FMCG markets.

About RedCloud Holdings plc

RedCloud’s mission is to build the intelligence infrastructure of global trade, through generation and aggregation of proprietary trading and market data from across the FMCG industry through its RedAI platform (“RedAI”). RedCloud provides market intelligence based on proprietary trading data across categories in each of its markets. The Company also delivers a ‘trading layer’ of products for use by its customers, to enable intelligent digital exchange of everyday consumer supplies of FMCG products across business supply chains, supported by a payments and lending ecosystem intended to streamline trade. RedCloud believes its Platform and associated products and services solve a decades-old problem of how to digitize trade at scale to generate data and intelligence to enable brands, distributors and retailers to maximize business performance across categories in high growth consumer markets.

Forward-Looking Statements

The information in this press release may include forward-looking statements within the meaning of the federal securities laws. These statements generally relate to future events or our future financial or operating performance. When used in this press release, words such as “expect,” “project,” “estimate,” “believe,” “anticipate,” “intend,” “plan,” “seek,” “forecast,” “target,” “predict,” “may,” “should,” “would,” “could,” and “will,” the negative of these terms and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. Forward-looking statements are based on management’s current expectations and assumptions, and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict, including, but not limited to, the successful execution of its joint venture strategy and launch in Türkiye and Saudi Arabian or whether the joint venture will be able to generate the targeted revenues over the next five years, the ability to leverage RedCloud’s future global developments in the use of AI and associated supply chain models through RedAI, the development and integration of real-time predictions through RedCloud’s RAID engine, including such development at RedCloud’s soon to be launched AI R&D hub at ITU Teknokent, the ability to scale globally through regional partnerships and embed intelligence across high-growth FMCG markets and the full enterprise deployment of the RAID engine. As a result, actual results could differ materially from those indicated in these forward-looking statements. When considering these forward-looking statements, you should keep in mind the risk factors and other cautionary statements in RedCloud’s described in “Cautionary Note Regarding Forward-Looking Statements,” “Item 3. Key Information – D. Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in RedCloud’s Annual Report on Form 20-F for the year ended December 31, 2024, which was filed with the Securities and Exchange Commission (the “SEC”) on May 16, 2025, as well as other documents filed by the Company with the SEC. RedCloud undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Information contained on, or that can be accessed through, the Company’s website or any other website or any social media is expressly not incorporated by reference into and is not a part of this press release.

Contacts:

Investor Relations
Investor.relations@redcloudtechnology.com

Media Relations
media@redcloudtechnology.com

The post RedCloud to Enter Live Deployment Phase as Combined Turkey and Saudi Joint Ventures Represent Up to $80 Million Revenue appeared first on Crypto Insider.

NEW YORK, April 19, 2026 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and March 24, 2026, both dates inclusive (the “Class Period”), of the important May 26, 2026 lead plaintiff deadline in the securities class action first filed by the Firm.

SO WHAT: If you purchased ImmunityBio securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the ImmunityBio class action, go to https://rosenlegal.com/submit-form/?case_id=17455 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 26, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) defendant Patrick Soon-Shiong materially overstated Anktiva’s capabilities; and (2) as a result, defendants’ statements about ImmunityBio’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the ImmunityBio class action, go to https://rosenlegal.com/submit-form/?case_id=17455 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————-

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40^th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        case@rosenlegal.com
        www.rosenlegal.com

The post ROSEN, A RANKED AND LEADING LAW FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX appeared first on Crypto Insider.

PARIS, April 19, 2026 (GLOBE NEWSWIRE) — From April 15–16, 2026, one of Europe’s premier blockchain events, Paris Blockchain Week 2026, concluded in Paris, France. Under the theme “The Bridge Between TradFi and Digital Assets,” the conference brought together regulators, financial institutions, Web3 projects, and infrastructure providers to explore the convergence of digital assets and traditional finance.

As a leading digital asset infrastructure provider, Cregis engaged with banks, payment providers, Web3 projects, and enterprise clients at Booth 20A. The company showcased its expertise in institutional custody, corporate wallets, and payment infrastructure, sharing its global experience and advancing its strategic presence in Europe.

From Narrative to Implementation: Europe Accelerates Institutional Adoption
On the regulatory front, frameworks such as MiCA are providing clarity and predictability for the market. Many financial institutions and payment providers at the conference noted that clear regulations are a key catalyst for institutional adoption and lay the foundation for broader applications of digital assets.

Stablecoins and on-chain payments emerged as a central discussion point. Across cross-border payments, corporate settlements, and treasury management, stablecoins are evolving from crypto-native tools into essential infrastructure connecting traditional finance with the on-chain economy. “How to build efficient, compliant settlement networks” became a frequent topic of discussion.

Corporate demand is also shifting. Unlike the past, which focused primarily on trading infrastructure, today’s market prioritizes system-wide capabilities such as custody security, treasury efficiency, and compliance and risk management frameworks. This trend reflects the growing integration of digital assets into enterprise-grade financial systems.

Paris Blockchain Week: A Key Convergence of Regulation, Institutions, and Technology
Paris Blockchain Week has reaffirmed its role as a critical connector in Europe’s blockchain ecosystem. From regulators outlining compliance pathways to traditional financial institutions exploring digital asset adoption, and Web3 enterprises developing infrastructure and real-world use cases, the conference highlighted a clear trend: digital assets are increasingly integrating with existing financial systems rather than existing as isolated ecosystems.

Europe’s unique position stands out. Its relatively mature regulatory landscape provides stability for industry development, while stringent compliance requirements set higher standards for infrastructure. This makes Europe not only a regulatory stronghold but also a testing ground for real-world digital asset adoption.

Cregis: Entering Europe Market Through Infrastructure Excellence
At the event, Cregis engaged with potential partners on institutional custody, stablecoin payments, and on-chain treasury management, confirming strong demand for compliant digital asset infrastructure in Europe.

Richard, Co-Founder of Cregis, said, “It’s clear from this conference that Europe is entering a development stage focused on compliance and infrastructure. Institutional clients prioritize security, scalability, and compatibility with existing financial systems, perfectly aligned with the capabilities we’ve built.”

He added that Cregis will continue expanding in Europe, exploring partnerships with local banks, payment providers, and enterprises to advance stablecoin payments, on-chain settlements, and corporate wallet solutions in real business scenarios.

“We are seeing double-digit growth across our pan-European client base, which reinforces our confidence in the region’s long-term opportunity,” said Shawn Yan, CEO and Founder of Cregis. “Europe’s evolving policy environment, especially the greater regulatory clarity created by MiCA, is opening up meaningful space for compliant digital asset adoption at scale. Given this momentum, we are formally increasing our investment in Europe in 2026 to better serve customers across the region. Our focus is to support different client needs with the right mix of payment infrastructure, governance controls and deployment models — from always-on treasury and settlement workflows to private, institution-grade custody infrastructure.”

As the digital asset industry enters a new phase, infrastructure for payments, custody, and treasury management is becoming a key bridge between TradFi and Web3. Paris Blockchain Week 2026 allowed Cregis to deepen connections with global partners and sharpen its strategic direction in Europe. With regulatory clarity improving and institutional demand rising, Europe is poised to become a major growth engine for digital asset infrastructure.

About Cregis
Cregis is a global provider of enterprise-grade digital asset infrastructure, offering secure, scalable, and compliant solutions for institutional clients.

Its core offerings—MPC-based self-custody wallets, Wallet-as-a-Service, and crypto payment solutions—are trusted by over 3,500 crypto exchanges, fintech companies, digital banks, payment service providers (PSPs), forex brokers, and Web3 businesses to seamlessly and securely accept, send, and manage digital assets.

Contact

Marketing Director
Janice
Cregis
janice@cregis.io

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5bebd304-3269-4385-9874-50701ff2353a

The post Cregis Shines at Paris Blockchain Week 2026, Accelerating European Expansion appeared first on Crypto Insider.

ESCMID: Sanofi’s Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study

• First head-to-head, double-blind, randomized phase 4 study powered to directly compare the tolerability profiles of these vaccines in adults in a real-world setting
• Results were presented today at the European Society of Clinical Microbiology and Infectious Diseases Global Congress in Munich, Germany.

Paris, April 18, 2026. Sanofi’s protein-based non-mRNA COVID-19 vaccine Nuvaxovid (NVX-CoV2705) demonstrated statistically significant lower systemic reactogenicity (the expected side effects that might occur following vaccination) compared to mNEXSPIKE (mRNA-1283), Moderna’s latest mRNA COVID-19 vaccine, across all pre-specified endpoints in the COMPARE study. The randomized, double-blind study, which enrolled 1,000 adults in the US, was presented at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress in Munich, Germany.

These results address a persistent challenge: despite the end of the pandemic, COVID-19 continues to cause significant hospitalizations and deaths globally, while placing considerable strain on health systems during seasonal peaks. Yet vaccination uptake remains low, with concerns about vaccine side effects ranking among the top reasons cited by adults for not getting vaccinated against COVID-19.

In the COMPARE study, when side effects did occur with Nuvaxovid, they were less severe and shorter in duration compared to mNEXSPIKE. Severe systemic symptoms (body-wide reactions such as fatigue, headache, or fever) that prevent people from carrying out their normal daily activities were more than 50% less frequent with Nuvaxovid, affecting fewer than one in ten Nuvaxovid recipients compared to one in five mNEXSPIKE recipients, an analysis of the data showed. Severe local symptoms (reactions at the injection site such as pain, redness, or swelling) with Nuvaxovid were rare, and more than 75% less frequent compared to mNEXSPIKE. This was reflected in the study participants’ own experience: those who received Nuvaxovid were nearly twice as likely as mNEXSPIKE recipients to say they would definitely choose the same vaccine type again the following year.

The study met its primary endpoint – the probability of experiencing at least one systemic reaction within seven days of vaccination – with statistical significance, with 91.6% of mNEXSPIKE recipients affected compared to 83.6% of Nuvaxovid recipients (risk difference: 8.0%; 95% CI: 4.0%–12%; p<0.001).

The study also showed that 61.3% of mNEXSPIKE recipients experienced moderate-to-severe (Grade 2 or 3) systemic symptoms versus 43.1% of Nuvaxovid recipients (risk difference: 18%; 95% CI: 12%–24%; p<0.001), and 58.7% of mNEXSPIKE recipients experienced moderate-to-severe local symptoms versus 38.7% of Nuvaxovid recipients (risk difference: 20%; 95% CI: 14%–26%; p<0.001).

“This study was designed to answer a question that matters deeply to clinicians and patients alike: how do different COVID-19 vaccines compare in terms of reactogenicity and patient experience? The answer is clear,” said Dr. Marcel E. Curlin, Principal Investigator of the COMPARE study and Professor of Medicine at Oregon Health & Science University. “Across every measure we evaluated, we observed that the recombinant protein-based vaccine consistently exhibited lower reactogenicity and less disruption to patient activities than the comparator mRNA vaccine. Individuals cite side effects as a reason they avoid COVID-19 vaccination. These differences could have a significant impact on improving vaccination uptake.”

“The patient experience with vaccination is essential, because it determines not only whether people get vaccinated, but also whether they come back year after year for routine protection,” said Thomas Triomphe, Executive Vice President, Vaccines, Sanofi. “These results show that Nuvaxovid can play a meaningful role in making routine COVID-19 vaccination a reality for more people, which is how we can help address the continued burden of this disease on patients and health systems.”

Beyond clinical measures, the COMPARE study also captured patient-reported outcomes reinforcing the real-world relevance of Nuvaxovid’s tolerability profile. Nuvaxovid recipients reported less disruption to daily activities, including work, school, recreational activities, and caretaking responsibilities, over the seven days following vaccination. Notably, more than half of all participants reported scheduling their vaccination on a specific day of the week in anticipation of potential side effects, highlighting the extent to which tolerability concerns shape vaccination behavior. Together, these findings suggest that a better tolerability experience may favor greater vaccine confidence and willingness to return for routine immunization.

About COVID-19
Coronavirus disease (COVID-19) is an infectious disease caused by the SARS-CoV-2 virus. Most people infected with the virus will experience mild to moderate respiratory illness and recover without requiring special treatment. However, some will become seriously ill resulting in hospitalization and death.

The disease not only causes immediate health impacts but also increases the long-term risk of cardiovascular complications, including heart attacks and strokes, and older adults hospitalized for COVID-19 face substantially higher mortality risk than those hospitalized for influenza. Older adults and those with chronic conditions – including cardiovascular disease, chronic lung disease, diabetes, and obesity – face the highest risk of severe illness. In the US, an estimated 74% of adults have at least one such risk factor, underscoring the scale of the vulnerable population that stands to benefit from effective and well-tolerated COVID-19 vaccination.

About Nuvaxovid
Nuvaxovid (NVX-CoV2705) is a protein-based, adjuvanted vaccine for active immunization to prevent COVID-19 caused by SARS-CoV-2. It is developed using the recombinant technology, an established platform with a long track record across multiple vaccine types. Nuvaxovid has been shown to have a tolerable side-effect profile suitable for routine vaccination and has also demonstrated high efficacy against COVID-19 as a primary vaccination in two pivotal phase 3 studies.

As the pandemic has now evolved into an endemic phase, having multiple vaccine options becomes increasingly important for sustainable public health strategies. Nuvaxovid offers healthcare systems a protein-based vaccine option with an established safety and tolerability profile to add to their routine vaccination programs. This diversity is particularly valuable for addressing vaccine hesitancy.

Nuvaxovid was originally licensed by Novavax. Sanofi is now market authorization holder for Nuvaxovid in the US, the EU and the United Kingdom. Building on its commercial launch in the US, Taiwan, and Morocco in 2025, Sanofi is expanding Nuvaxovid’s availability to additional markets – including the United Kingdom, Germany, and Canada – from 2026 onwards.

About Sanofi
Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

Media Relations
Sandrine Guendoul | +33 6 25 09 14 25 | sandrine.guendoul@sanofi.com
Evan Berland | +1 215 432 0234 | evan.berland@sanofi.com
Léo Le Bourhis | +33 6 75 06 43 81 | leo.lebourhis@sanofi.com
Victor Rouault | +1 617 356 4751 | victor.rouault@sanofi.com
Timothy Gilbert | +1 516 521 2929 | timothy.gilbert@sanofi.com
Léa Ubaldi | +33 6 30 19 66 46 | lea.ubaldi@sanofi.com
Ekaterina Pesheva | +1 410 926 6780 | ekaterina.pescheva@sanofi.com

Investor Relations
Thomas Kudsk Larsen |+ 44 7545 513 693 | thomas.larsen@sanofi.com
Alizé Kaisserian | + 33 6 47 04 12 11 | alize.kaisserian@sanofi.com
Keita Browne | + 1 781 249 1766 | keita.browne@sanofi.com
Nathalie Pham | + 33 7 85 93 30 17 | nathalie.pham@sanofi.com
Nina Goworek | +1 908 569 7086 | nina.goworek@sanofi.com
Thibaud Châtelet | + 33 6 80 80 89 90 | thibaud.chatelet@sanofi.com
Yun Li | +33 6 84 00 90 72 | yun.li3@sanofi.com

Sanofi forward-looking statement
This press release contains forward-looking statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions regarding the marketing and other potential of the product; regarding potential future events and revenues from the product. Words such as “expect,” “anticipate,” “believe,” “intend,” “estimate,” “plan,” “can,” “contemplate,” “could,” “is designed to,” “may,” “might,” “potential,” “objective,” “attempt,” “target,” “project,” “strategy,” “strive,” “desire,” “predict,” “forecast,” “ambition,” “guideline,” “seek,” “should,” “will,” “goal,” or the negative of these and similar expressions are intended to identify forward-looking statements. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks, uncertainties and assumptions include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful; authorities’ decisions regarding whether and when to approve a product candidate; political pressure in the United States to mandate lower drug prices including “most favored nation” pricing for State Medicaid programs; the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues; competition in general; risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the French Markets Authority (AMF) made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2025 or contained in our periodic reports on Form 6-K. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. In light of these risks, uncertainties and assumptions, you should not place undue reliance on any forward-looking statements contained herein.

Attachment

• Press Release

The post Press Release: ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study appeared first on Crypto Insider.

Aurora, CO, April 18, 2026 (GLOBE NEWSWIRE) — Disclaimer: This release is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any new supplement, especially if you have existing health conditions or are currently taking medication. If purchases are made through referenced links, a commission may be earned at no additional cost to the reader. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article contains affiliate links. If you purchase through these links, a commission may be earned at no additional cost to you.

This informational release outlines how product-related information is presented across the official VigoSurge pages, including ingredient descriptions, general safety considerations, and common consumer questions about the formula.

In this context, the phrase “claims evaluated” refers exclusively to how VigoSurge describes its own product information, ingredient profile, and published policies. It does not represent an independent clinical evaluation, third-party research, or medical assessment of the product.

The term “analyzing” in this release refers to a structured presentation of how the VigoSurge formula and its ingredients are described by the brand — not an independent evaluation or comparative product research.

References to benefits, side effects risk, and customer complaints reflect commonly searched consumer questions and are included to address public interest topics in a clear, informational manner. These terms do not imply verified outcomes, guaranteed results, or confirmed adverse findings.

Search activity around terms such as “VigoSurge review,” “does VigoSurge work,” “VigoSurge side effects,” and “VigoSurge complaints” reflects a need for straightforward answers about what the product is, what the label discloses, and what to expect before purchasing. That is exactly what this release covers.

Readers who want to review current product details before reading further can do so now: View the current VigoSurge offer (official VigoSurge page).

VigoSurge Product Overview

VigoSurge is a dietary supplement positioned to support male sexual health, energy, stamina, libido, and vitality in adult men. Purchases are processed through BuyGoods as the authorized retailer, with customer support available at support@vigosurge.com.

VigoSurge describes the formula as a once-daily capsule. The formula is non-GMO, vegan, and gluten-free, with no chemical coatings or non-essential fillers, and is manufactured in an FDA-registered and inspected facility in accordance with USDA National Organic Program handling standards. The formula is described as containing zero dangerous stimulants and is stated to be non-habit-forming.

VigoSurge is a dietary supplement. It is not a prescription medication, not a substitute for physician-supervised care, and not a treatment for any diagnosed condition. Any male sexual health concern that may require medical evaluation should be discussed with a qualified healthcare provider.

VigoSurge describes this as an enhanced 14-in-1 herbal formula described as supporting multiple aspects of male sexual health. The 14 active ingredients are organized into five functional support categories as presented on the product page: premium energy and stamina, essential blood circulation and cardiovascular health, libido enhancement, hormonal and prostate support, and overall health and well-being.

VigoSurge Ingredient Information

The VigoSurge formula includes 14 active ingredients organized into functional categories as described on the official product page. What follows reflects how VigoSurge presents each ingredient group, along with the general research landscape for those individual compounds.

Published research exists on certain individual ingredients in the male health and sexual wellness category. Several compounds included in the VigoSurge formula have been studied individually in peer-reviewed literature related to libido, circulation, and prostate health. Based on the materials referenced by VigoSurge, the cited research relates to individual ingredients rather than a published clinical trial of the finished formula. This is consistent with how most dietary supplements in this category are positioned — ingredient-level research establishes a scientific rationale for each compound’s inclusion, while product-level clinical trials of the finished formula are uncommon across the supplement industry as a whole.

Premium Energy and Stamina: Panax Ginseng is included in the formula and described by VigoSurge as supporting stamina and energy. Ginseng has a substantial human research profile, with published controlled trials examining its adaptogenic and energizing properties. A 2008 meta-analysis reviewed randomized controlled trials and found evidence that Korean red ginseng may support erectile function, though the authors called for more rigorous trials to confirm those findings.

Muira Puama is included in the formula and described by VigoSurge as “potency wood,” an Amazonian botanical with a long history of traditional use in male health contexts. Human clinical data on muira puama remains limited relative to its traditional use record.

Inosine is included in the formula and described by VigoSurge as supporting energy production. It is a nucleoside compound that has been studied in athletic performance contexts.

Blood Circulation and Cardiovascular Support: Ginkgo Biloba is included in the formula and described by VigoSurge as helping maintain healthy blood flow and circulation. Published flavonoid research supports vascular effects at studied dosages, including ginkgo’s potential role in cGMP phosphodiesterase inhibition, which is relevant to vascular blood flow.

Hawthorn is included in the formula and described by VigoSurge as supporting cardiovascular health. It has an established research profile in cardiovascular medicine.

Cayenne Pepper is included in the formula and described by VigoSurge as promoting healthy blood flow through its capsaicin content. Capsaicin has published research supporting temporary circulatory effects.

Niacin (Vitamin B3) is included in the formula and described by VigoSurge as helping maintain healthy blood circulation. Niacin has well-established roles in cardiovascular health and is an FDA-recognized nutrient with defined Daily Values.

Libido Support: Epimedium (Horny Goat Weed) is included in the formula and described by VigoSurge as supporting libido. It contains icariin, a compound examined in published research for its potential role in supporting erectile function through PDE5 inhibition mechanisms. Human studies on icariin remain limited, and most controlled findings come from preclinical models.

Damiana is included in the formula and described by VigoSurge as supporting sexual desire. Traditional use data for this botanical is more robust than its clinical human trial record.

Catuaba is included in the formula and described by VigoSurge as supporting libido. It is a Brazilian bark with traditional male health applications and limited controlled human research.

Hormonal and Prostate Support: Saw Palmetto is included in the formula and described by VigoSurge as promoting prostate health. It has one of the stronger individual research profiles among the formula’s ingredients, with clinical trials published in urology and men’s health journals examining its potential role in supporting prostate function and urinary health in men over 40.

Overall Well-Being: Oat Straw is included in the formula and described by VigoSurge as supporting a healthy nervous system.

Vitamin E is included in the formula and described by VigoSurge as an antioxidant supporting overall health. It is a well-studied fat-soluble nutrient with recognized dietary roles.

The VigoSurge product page references 19 published scientific citations available on the brand’s website. Those citations describe compound-level research on individual ingredients, not product-level outcomes for the finished VigoSurge formula. Readers who want to review those citations can find them directly on the official product page.

Individual ingredient dosages are not fully disclosed in VigoSurge’s publicly available product materials. Readers working with a healthcare provider who need specific ingredient amounts for clinical comparison can contact VigoSurge directly for additional information.

Readers who want to review the full ingredient information can do so here: View the current VigoSurge offer (official VigoSurge page).

Safety Considerations and Label Cautions

VigoSurge is a dietary supplement containing botanical extracts, plant-derived compounds, vitamins, and minerals. The product page includes the standard recommendation that individuals with a known medical condition should consult a physician before using this or any dietary supplement.

Safety considerations in this release are limited to general label cautions and the importance of consulting a qualified healthcare professional before use. VigoSurge does not position this formula as equivalent to a pharmaceutical drug evaluation, and nothing in this release should be interpreted that way.

Several ingredients included in the formula warrant awareness for specific populations, based on published pharmacological literature. Ginkgo Biloba, included for its role in supporting blood flow, has mild antiplatelet properties documented in published research and may interact with blood thinners or anticoagulant medications. Panax Ginseng, included for its role in supporting stamina and energy, may interact with blood pressure medications, diabetes medications, and anticoagulants. Cayenne Pepper, included for its role in supporting healthy circulation, may cause gastrointestinal sensitivity in some individuals. Epimedium, included for its role in supporting libido, has been studied in the context of hormonal mechanisms, though human data at standard supplement dosages remains limited.

Anyone taking prescription medications — including those used for urological, cardiovascular, hormonal, or metabolic health — should discuss any new supplement with their prescribing physician or pharmacist before use. Only a licensed clinician can determine whether any dietary supplement is appropriate for an individual’s personal health situation.

The FDA has not evaluated the safety or efficacy claims for this product. The VigoSurge product page includes the standard regulatory disclosure: these statements have not been evaluated by the Food and Drug Administration, and this product is not intended to diagnose, treat, cure, or prevent any disease.

Understanding Consumer Search Topics: VigoSurge Complaints, Side Effects, and Product Questions

The phrase “customer complaints” in this release reflects common pre-purchase search behavior and typically relates to questions about shipping, refund eligibility, order support, and expectation management. It is not intended to indicate verified product defects, regulatory findings, or widespread adverse reports.

Search activity around “VigoSurge complaints” or “VigoSurge side effects” almost always comes from people doing exactly what they should be doing before ordering a supplement — verifying the refund policy, understanding what to realistically expect, and confirming the product is a reasonable fit for their situation. Those are the right questions to ask, and they deserve clear answers.

On outcomes: The VigoSurge product page provides information about its ingredients’ individual research contexts across the male sexual health and vitality category. No dietary supplement in this category can guarantee outcomes equivalent to prescription treatment or medical intervention. Individual response depends on age, baseline health, existing medications, lifestyle, and consistency of use. The product page recommends giving the formula a fair chance, as individual response timelines vary.

On refund eligibility: The published VigoSurge refund policy provides a 60-day money-back window from the date of delivery. Returns must include all received items shipped back to the return address. Return shipping is at the customer’s expense. Full policy details are published on the official VigoSurge page and should be reviewed before ordering.

On pricing and package options: Current pricing, package options, and refund policies are published on the official VigoSurge page and may change over time. Readers should verify all current details directly on the official page before making any purchase decision.

For direct support inquiries, order questions, or refund requests:

Support Email: support@vigosurge.com
BuyGoods Order Support: https://www.buygoods.com/orderlookup
BuyGoods Phone: +1-302-200-3480
Return Address: 19655 E 35th Dr #100, Aurora, CO 80011, USA

Who the VigoSurge Formula Is Designed For

Based on the product page’s stated positioning, VigoSurge is positioned for adult men who want to incorporate a plant-based male health supplement into a broader wellness routine that already includes professional medical guidance, regular physical activity, and balanced nutrition.

The once-daily capsule format and the clean-label positioning — non-GMO, vegan, gluten-free, and stimulant-free — reflect the quality standards stated on the VigoSurge product page, which may be relevant to men who pay close attention to ingredient standards and manufacturing transparency when selecting supplements.

The formula’s coverage across five functional support categories may appeal to men looking for a single product that addresses energy support, circulation support, libido support, and prostate wellness, rather than managing several single-ingredient supplements separately.

Men with diagnosed conditions that require physician-supervised pharmaceutical treatment, those who need fully disclosed per-ingredient dosages for clinical comparison, or those expecting immediate or dramatic results from supplementation alone may want to discuss their options with a healthcare provider before ordering.

VigoSurge is a dietary supplement. Supplements are regulated differently than pharmaceutical drugs, and the FDA does not evaluate dietary supplement claims for efficacy before products reach the market.

Reference Notes

On ingredient research: The research referenced in this release reflects findings on specific isolated compounds under specific study conditions. It does not constitute clinical proof for the finished VigoSurge formula. Ingredient-level research and product-level clinical evidence are separate considerations — both should be understood clearly when evaluating any dietary supplement.

On the FDA-registered facility claim: An FDA-registered facility is a manufacturing location that has registered with the FDA as required by federal law, making it subject to FDA inspection. Registration does not mean the FDA has reviewed, approved, or endorsed any specific product manufactured at that location.

On dietary supplement regulation: Under current federal regulations, dietary supplements do not require FDA approval before being sold. The FDA does not evaluate supplement efficacy claims before products reach the market. The VigoSurge label includes the standard regulatory statement reflecting this framework.

On refund terms: The 60-day refund window, return shipping responsibility, and accepted return conditions are published on the official VigoSurge page. Readers should review those terms directly before completing any purchase and keep all order confirmation information on hand.

On testimonials: The VigoSurge product page includes testimonials attributed to named individuals. The published terms state that testimonial results are not a guarantee of outcomes, that individual results will vary, and that names and personal identifying information may have been changed to protect privacy.

On professional consultation: Male sexual health concerns can reflect conditions that benefit from or require professional medical evaluation. Anyone experiencing significant changes in sexual function, urinary health, or related health changes should consult a qualified healthcare provider rather than relying on any supplement as a primary response.

Current Offer and Order Information

Current offer details, package availability, shipping terms, refund conditions, and any included materials are presented on the official VigoSurge page and may change over time. Readers should verify the latest information directly on the official page before making any purchase decision.

Order and support inquiries can be directed to support@vigosurge.com. BuyGoods order support is available at https://www.buygoods.com/orderlookup or by phone at +1-302-200-3480. Returns are accepted at 19655 E 35th Dr #100, Aurora, CO 80011, USA, within the 60-day window described in the official refund policy.

Complete product details, the full ingredient overview, current pricing, and published policies are available here: View the current VigoSurge offer (official VigoSurge page).

Consumer Questions

What does “claims evaluated” mean in this release?

“Claims evaluated” in this release refers exclusively to how VigoSurge presents its own product information, ingredient descriptions, and published policies. It is not an independent clinical determination, a third-party review, or a verdict on product efficacy.

What does “analyzing” mean in the title of this release?

“Analyzing” in this release refers to a structured presentation of how the VigoSurge formula and its ingredients are described by the brand — not an independent evaluation or comparative product review.

Is VigoSurge FDA approved?

VigoSurge is a dietary supplement. Under current federal regulations, dietary supplements do not require FDA approval before being sold. The FDA does not evaluate dietary supplement efficacy claims before products reach the market. The VigoSurge product page states the formula is manufactured in an FDA-registered and inspected facility in accordance with USDA National Organic Program handling standards — which relates to manufacturing standards, not product approval or endorsement of any health claims.

What does “FDA-registered facility” mean?

An FDA-registered facility is a manufacturing location that has registered with the FDA as required by federal law, making it subject to FDA inspection. Registration does not mean the FDA has reviewed, approved, or endorsed any specific product manufactured at that location.

Is VigoSurge a treatment for sexual dysfunction or prostate conditions?

No. VigoSurge is a dietary supplement and is not a substitute for physician-supervised care, diagnosis, or prescription treatment for any condition. Anyone with a diagnosed condition or significant symptoms should consult a urologist or qualified healthcare provider. This product is not intended to diagnose, treat, cure, or prevent any disease.

What do the “customer complaints” references in this release address?

The phrase “customer complaints” in this release reflects common pre-purchase search behavior that typically relates to questions about shipping, refund eligibility, order support, and expectation management. It is not intended to indicate verified product defects, regulatory findings, or adverse determinations of any kind. For direct support, contact support@vigosurge.com or BuyGoods at +1-302-200-3480.

What side effects risk does the label disclose?

The VigoSurge product page recommends that individuals with a known medical condition consult a physician before use. Several ingredients in the formula — including Ginkgo Biloba, Panax Ginseng, and Cayenne Pepper — have published interaction profiles with certain prescription medications. Anyone taking blood thinners, blood pressure medications, or diabetes medications should consult their prescribing physician or pharmacist before adding any multi-botanical supplement. Individual tolerability depends on personal health factors that only a clinician can properly evaluate.

How does the refund policy work?

The published VigoSurge refund policy provides a 60-day window from the date of delivery. All received items should be shipped to: 19655 E 35th Dr #100, Aurora, CO 80011, USA. Return shipping is at the customer’s expense. Refunds are processed upon receipt of the returned package. Direct questions to support@vigosurge.com or BuyGoods order support at +1-302-200-3480.

Does VigoSurge contain stimulants?

The VigoSurge product page describes the formula as containing zero dangerous stimulants and states it is non-habit-forming. Anyone with sensitivities to botanical ingredients should review the full ingredient list and consult a pharmacist or physician before use.

Where is VigoSurge sold?

The VigoSurge product page states the supplement is not sold in stores or elsewhere online and is available only through the official page. Purchases made through unauthorized sellers may not qualify for the official refund policy. The official source is accessible here: View the current VigoSurge offer (official VigoSurge page).

Is VigoSurge appropriate for all ages?

The VigoSurge product page positions the supplement for adult men. The page recommends consulting a physician before use if you have a medical condition or take medications — guidance that is especially relevant for men over 50, who are statistically more likely to be managing chronic conditions or taking prescription therapies.

How long does VigoSurge take to show results?

The VigoSurge product page recommends giving the formula a fair chance, as some people may take longer to respond than others and individual response timelines vary. Individual results, including the degree of change and time to notice any difference, will vary from person to person.

Contact Information

Brand: VigoSurge
Return Address: 19655 E 35th Dr #100, Aurora, CO 80011, USA
Support Email: support@vigosurge.com
BuyGoods Order Support: https://www.buygoods.com/orderlookup
BuyGoods Phone: +1-302-200-3480

Disclaimers

FDA Health Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Always consult your physician before starting any new supplement, especially if you have existing health conditions, take medications, or are pregnant or nursing.

Professional Medical Disclaimer: This release is for informational purposes only and does not constitute medical advice. VigoSurge is a dietary supplement, not a medication or treatment for any diagnosed condition. If you are currently taking medications, managing an existing health condition, are pregnant or nursing, or are considering changes to your health regimen, consult your physician before starting VigoSurge or any new supplement. Do not change, adjust, or discontinue any medications or prescribed treatments without your physician’s guidance and approval.

Ingredient Interaction Notice: Several ingredients in the VigoSurge formula — including Ginkgo Biloba, Panax Ginseng, and Cayenne Pepper — have published interaction profiles with certain prescription medications, including blood thinners, blood pressure medications, and diabetes medications. Anyone taking prescription therapies should consult a physician or pharmacist before use. This notice is not a complete interaction review and does not replace professional medical guidance.

Results May Vary: Individual results will vary based on factors including age, baseline health, lifestyle, consistency of use, current medications, genetic factors, and other individual variables. Results are not guaranteed. Customer experiences referenced in any marketing materials represent individual accounts and should not be interpreted as typical or guaranteed outcomes.

Affiliate Disclosure: If purchases are made through referenced links in this release, a commission may be earned at no additional cost to the buyer. This compensation does not influence the accuracy or integrity of the information presented. All descriptions reflect information from the official VigoSurge product page and label disclosures.

Pricing and Offer Terms: All pricing, shipping terms, bonus materials, and promotional offers are based on information published on the official product page at the time of this release and are subject to change without notice. Always verify current terms directly on the official VigoSurge page before completing any purchase.

The post VigoSurge Claims Evaluated: Analyzing the Ingredients' Benefits, Side Effects Risk and Customer Complaints appeared first on Crypto Insider.